nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—P-Glycoprotein Inhibitors—Crizotinib—lung cancer	0.284	1	CiPCiCtD
Vemurafenib—melanoma—lung cancer	0.24	1	CtDrD
Vemurafenib—RAF1—lung cancer	0.0993	0.468	CbGaD
Vemurafenib—BRAF—lung cancer	0.0688	0.325	CbGaD
Vemurafenib—ABCG2—lung cancer	0.0306	0.144	CbGaD
Vemurafenib—ORM1—Gefitinib—lung cancer	0.0156	0.0892	CbGbCtD
Vemurafenib—ALB—lung cancer	0.0133	0.0629	CbGaD
Vemurafenib—ABCG2—Topotecan—lung cancer	0.0104	0.0595	CbGbCtD
Vemurafenib—ABCG2—Gefitinib—lung cancer	0.00952	0.0544	CbGbCtD
Vemurafenib—ABCG2—Teniposide—lung cancer	0.00923	0.0528	CbGbCtD
Vemurafenib—ORM1—Erlotinib—lung cancer	0.00922	0.0527	CbGbCtD
Vemurafenib—ABCC1—Paclitaxel—lung cancer	0.0077	0.044	CbGbCtD
Vemurafenib—ABCC1—Irinotecan—lung cancer	0.0076	0.0434	CbGbCtD
Vemurafenib—ABCC1—Vinblastine—lung cancer	0.00675	0.0386	CbGbCtD
Vemurafenib—ALB—Gefitinib—lung cancer	0.00656	0.0375	CbGbCtD
Vemurafenib—ABCC1—Etoposide—lung cancer	0.00608	0.0348	CbGbCtD
Vemurafenib—ABCG2—Erlotinib—lung cancer	0.00563	0.0322	CbGbCtD
Vemurafenib—ABCC1—Docetaxel—lung cancer	0.00557	0.0318	CbGbCtD
Vemurafenib—ABCG2—Paclitaxel—lung cancer	0.00515	0.0295	CbGbCtD
Vemurafenib—ABCG2—Irinotecan—lung cancer	0.00508	0.0291	CbGbCtD
Vemurafenib—ABCC1—Doxorubicin—lung cancer	0.00415	0.0237	CbGbCtD
Vemurafenib—ABCG2—Cisplatin—lung cancer	0.00414	0.0237	CbGbCtD
Vemurafenib—ABCG2—Etoposide—lung cancer	0.00407	0.0233	CbGbCtD
Vemurafenib—ABCC1—Methotrexate—lung cancer	0.00402	0.023	CbGbCtD
Vemurafenib—ALB—Erlotinib—lung cancer	0.00388	0.0222	CbGbCtD
Vemurafenib—ABCG2—Docetaxel—lung cancer	0.00373	0.0213	CbGbCtD
Vemurafenib—ALB—Irinotecan—lung cancer	0.0035	0.02	CbGbCtD
Vemurafenib—CYP2D6—Gefitinib—lung cancer	0.00323	0.0185	CbGbCtD
Vemurafenib—ABCG2—Doxorubicin—lung cancer	0.00278	0.0159	CbGbCtD
Vemurafenib—ABCG2—Methotrexate—lung cancer	0.00269	0.0154	CbGbCtD
Vemurafenib—CYP2D6—Vinorelbine—lung cancer	0.00249	0.0142	CbGbCtD
Vemurafenib—CYP1A2—Erlotinib—lung cancer	0.00232	0.0133	CbGbCtD
Vemurafenib—CYP3A4—Topotecan—lung cancer	0.00225	0.0129	CbGbCtD
Vemurafenib—CYP3A4—Gefitinib—lung cancer	0.00206	0.0118	CbGbCtD
Vemurafenib—CYP3A4—Teniposide—lung cancer	0.00199	0.0114	CbGbCtD
Vemurafenib—CYP2D6—Erlotinib—lung cancer	0.00191	0.0109	CbGbCtD
Vemurafenib—ALB—Methotrexate—lung cancer	0.00185	0.0106	CbGbCtD
Vemurafenib—CYP1A2—Etoposide—lung cancer	0.00168	0.0096	CbGbCtD
Vemurafenib—CYP3A4—Vinorelbine—lung cancer	0.00158	0.00906	CbGbCtD
Vemurafenib—CYP2D6—Vinblastine—lung cancer	0.00154	0.00878	CbGbCtD
Vemurafenib—CYP3A4—Crizotinib—lung cancer	0.00126	0.00721	CbGbCtD
Vemurafenib—CYP3A4—Erlotinib—lung cancer	0.00122	0.00695	CbGbCtD
Vemurafenib—CYP3A4—Paclitaxel—lung cancer	0.00111	0.00637	CbGbCtD
Vemurafenib—CYP3A4—Irinotecan—lung cancer	0.0011	0.00628	CbGbCtD
Vemurafenib—RAF1—Topotecan—Irinotecan—lung cancer	0.000988	1	CbGdCrCtD
Vemurafenib—CYP3A4—Vinblastine—lung cancer	0.000976	0.00558	CbGbCtD
Vemurafenib—CYP2D6—Doxorubicin—lung cancer	0.000944	0.0054	CbGbCtD
Vemurafenib—CYP3A4—Etoposide—lung cancer	0.00088	0.00503	CbGbCtD
Vemurafenib—CYP3A4—Docetaxel—lung cancer	0.000805	0.0046	CbGbCtD
Vemurafenib—CYP3A4—Doxorubicin—lung cancer	0.0006	0.00343	CbGbCtD
Vemurafenib—Etoricoxib—CYP2E1—lung cancer	0.000399	0.619	CrCbGaD
Vemurafenib—RAF1—respiratory system—lung cancer	0.000317	0.0785	CbGeAlD
Vemurafenib—ALB—mammary gland—lung cancer	0.000288	0.0713	CbGeAlD
Vemurafenib—BRAF—bone marrow—lung cancer	0.000279	0.069	CbGeAlD
Vemurafenib—RAF1—epithelium—lung cancer	0.000265	0.0656	CbGeAlD
Vemurafenib—RAF1—bronchus—lung cancer	0.000261	0.0646	CbGeAlD
Vemurafenib—BRAF—lung—lung cancer	0.000253	0.0626	CbGeAlD
Vemurafenib—Etoricoxib—PTGS2—lung cancer	0.000246	0.381	CrCbGaD
Vemurafenib—RAF1—trachea—lung cancer	0.000235	0.058	CbGeAlD
Vemurafenib—RAF1—cardiac atrium—lung cancer	0.00022	0.0545	CbGeAlD
Vemurafenib—RAF1—bone marrow—lung cancer	0.000186	0.046	CbGeAlD
Vemurafenib—BRAF—lymph node—lung cancer	0.000173	0.0428	CbGeAlD
Vemurafenib—RAF1—lung—lung cancer	0.000169	0.0417	CbGeAlD
Vemurafenib—ABCC1—bronchus—lung cancer	0.000131	0.0323	CbGeAlD
Vemurafenib—ORM1—bone marrow—lung cancer	0.000128	0.0318	CbGeAlD
Vemurafenib—CYP1A2—respiratory system—lung cancer	0.000126	0.0312	CbGeAlD
Vemurafenib—ABCC1—trachea—lung cancer	0.000117	0.029	CbGeAlD
Vemurafenib—ORM1—lung—lung cancer	0.000116	0.0288	CbGeAlD
Vemurafenib—RAF1—lymph node—lung cancer	0.000115	0.0285	CbGeAlD
Vemurafenib—ABCC1—cardiac atrium—lung cancer	0.00011	0.0272	CbGeAlD
Vemurafenib—ABCC1—lung—lung cancer	8.42e-05	0.0208	CbGeAlD
Vemurafenib—ORM1—lymph node—lung cancer	7.96e-05	0.0197	CbGeAlD
Vemurafenib—ABCG2—bone marrow—lung cancer	7.7e-05	0.019	CbGeAlD
Vemurafenib—ALB—lymph node—lung cancer	6.98e-05	0.0173	CbGeAlD
Vemurafenib—ABCG2—lung—lung cancer	6.97e-05	0.0172	CbGeAlD
Vemurafenib—CYP1A2—lung—lung cancer	6.71e-05	0.0166	CbGeAlD
Vemurafenib—ABCC1—lymph node—lung cancer	5.76e-05	0.0142	CbGeAlD
Vemurafenib—ABCG2—lymph node—lung cancer	4.77e-05	0.0118	CbGeAlD
Vemurafenib—Diarrhoea—Erlotinib—lung cancer	3.99e-05	0.00101	CcSEcCtD
Vemurafenib—Body temperature increased—Vinorelbine—lung cancer	3.98e-05	0.00101	CcSEcCtD
Vemurafenib—Oedema peripheral—Docetaxel—lung cancer	3.98e-05	0.00101	CcSEcCtD
Vemurafenib—Connective tissue disorder—Docetaxel—lung cancer	3.97e-05	0.00101	CcSEcCtD
Vemurafenib—Nervous system disorder—Gemcitabine—lung cancer	3.97e-05	0.00101	CcSEcCtD
Vemurafenib—Myalgia—Cisplatin—lung cancer	3.94e-05	0.000997	CcSEcCtD
Vemurafenib—Skin disorder—Gemcitabine—lung cancer	3.93e-05	0.000996	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—lung cancer	3.91e-05	0.00099	CcSEcCtD
Vemurafenib—Dizziness—Topotecan—lung cancer	3.89e-05	0.000986	CcSEcCtD
Vemurafenib—Hypotension—Irinotecan—lung cancer	3.88e-05	0.000983	CcSEcCtD
Vemurafenib—Vomiting—Vinblastine—lung cancer	3.85e-05	0.000976	CcSEcCtD
Vemurafenib—Dizziness—Erlotinib—lung cancer	3.85e-05	0.000976	CcSEcCtD
Vemurafenib—Erythema multiforme—Docetaxel—lung cancer	3.82e-05	0.000968	CcSEcCtD
Vemurafenib—Headache—Vinblastine—lung cancer	3.8e-05	0.000962	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Methotrexate—lung cancer	3.79e-05	0.000961	CcSEcCtD
Vemurafenib—Hypotension—Gemcitabine—lung cancer	3.78e-05	0.000958	CcSEcCtD
Vemurafenib—Eye disorder—Docetaxel—lung cancer	3.78e-05	0.000957	CcSEcCtD
Vemurafenib—Anaphylactic shock—Cisplatin—lung cancer	3.77e-05	0.000956	CcSEcCtD
Vemurafenib—Cardiac disorder—Docetaxel—lung cancer	3.75e-05	0.00095	CcSEcCtD
Vemurafenib—Infection—Cisplatin—lung cancer	3.75e-05	0.000949	CcSEcCtD
Vemurafenib—Vomiting—Topotecan—lung cancer	3.74e-05	0.000949	CcSEcCtD
Vemurafenib—Rash—Topotecan—lung cancer	3.71e-05	0.000941	CcSEcCtD
Vemurafenib—Hypersensitivity—Vinorelbine—lung cancer	3.71e-05	0.00094	CcSEcCtD
Vemurafenib—Dermatitis—Topotecan—lung cancer	3.71e-05	0.00094	CcSEcCtD
Vemurafenib—Vomiting—Erlotinib—lung cancer	3.7e-05	0.000938	CcSEcCtD
Vemurafenib—Nervous system disorder—Cisplatin—lung cancer	3.7e-05	0.000937	CcSEcCtD
Vemurafenib—Cough—Etoposide—lung cancer	3.7e-05	0.000936	CcSEcCtD
Vemurafenib—Headache—Topotecan—lung cancer	3.69e-05	0.000935	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Gemcitabine—lung cancer	3.69e-05	0.000934	CcSEcCtD
Vemurafenib—Rash—Erlotinib—lung cancer	3.67e-05	0.000931	CcSEcCtD
Vemurafenib—Dermatitis—Erlotinib—lung cancer	3.67e-05	0.00093	CcSEcCtD
Vemurafenib—Angiopathy—Docetaxel—lung cancer	3.67e-05	0.000929	CcSEcCtD
Vemurafenib—Skin disorder—Cisplatin—lung cancer	3.66e-05	0.000928	CcSEcCtD
Vemurafenib—Headache—Erlotinib—lung cancer	3.65e-05	0.000925	CcSEcCtD
Vemurafenib—Pain in extremity—Doxorubicin—lung cancer	3.65e-05	0.000924	CcSEcCtD
Vemurafenib—Mediastinal disorder—Docetaxel—lung cancer	3.64e-05	0.000923	CcSEcCtD
Vemurafenib—Chills—Docetaxel—lung cancer	3.63e-05	0.000919	CcSEcCtD
Vemurafenib—Cough—Paclitaxel—lung cancer	3.62e-05	0.000918	CcSEcCtD
Vemurafenib—Asthenia—Vinorelbine—lung cancer	3.61e-05	0.000916	CcSEcCtD
Vemurafenib—Decreased appetite—Irinotecan—lung cancer	3.61e-05	0.000915	CcSEcCtD
Vemurafenib—Eosinophilia—Methotrexate—lung cancer	3.6e-05	0.000913	CcSEcCtD
Vemurafenib—Nausea—Vinblastine—lung cancer	3.6e-05	0.000912	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Irinotecan—lung cancer	3.59e-05	0.000909	CcSEcCtD
Vemurafenib—Fatigue—Irinotecan—lung cancer	3.58e-05	0.000907	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	3.58e-05	0.000907	CcSEcCtD
Vemurafenib—Alopecia—Docetaxel—lung cancer	3.57e-05	0.000905	CcSEcCtD
Vemurafenib—Pruritus—Vinorelbine—lung cancer	3.56e-05	0.000903	CcSEcCtD
Vemurafenib—Constipation—Irinotecan—lung cancer	3.55e-05	0.0009	CcSEcCtD
Vemurafenib—Arthralgia—Paclitaxel—lung cancer	3.53e-05	0.000895	CcSEcCtD
Vemurafenib—Myalgia—Paclitaxel—lung cancer	3.53e-05	0.000895	CcSEcCtD
Vemurafenib—Hypotension—Cisplatin—lung cancer	3.53e-05	0.000893	CcSEcCtD
Vemurafenib—Erythema—Docetaxel—lung cancer	3.52e-05	0.000891	CcSEcCtD
Vemurafenib—Malnutrition—Docetaxel—lung cancer	3.52e-05	0.000891	CcSEcCtD
Vemurafenib—Decreased appetite—Gemcitabine—lung cancer	3.52e-05	0.000891	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	3.51e-05	0.000889	CcSEcCtD
Vemurafenib—Nausea—Topotecan—lung cancer	3.5e-05	0.000886	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Gemcitabine—lung cancer	3.49e-05	0.000885	CcSEcCtD
Vemurafenib—Fatigue—Gemcitabine—lung cancer	3.49e-05	0.000884	CcSEcCtD
Vemurafenib—Constipation—Gemcitabine—lung cancer	3.46e-05	0.000877	CcSEcCtD
Vemurafenib—Nausea—Erlotinib—lung cancer	3.46e-05	0.000877	CcSEcCtD
Vemurafenib—Anaphylactic shock—Etoposide—lung cancer	3.46e-05	0.000875	CcSEcCtD
Vemurafenib—Diarrhoea—Vinorelbine—lung cancer	3.45e-05	0.000873	CcSEcCtD
Vemurafenib—Dysgeusia—Docetaxel—lung cancer	3.45e-05	0.000873	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Cisplatin—lung cancer	3.44e-05	0.000871	CcSEcCtD
Vemurafenib—Infection—Etoposide—lung cancer	3.43e-05	0.00087	CcSEcCtD
Vemurafenib—Back pain—Docetaxel—lung cancer	3.4e-05	0.000862	CcSEcCtD
Vemurafenib—Anaphylactic shock—Paclitaxel—lung cancer	3.39e-05	0.000858	CcSEcCtD
Vemurafenib—Infection—Paclitaxel—lung cancer	3.37e-05	0.000853	CcSEcCtD
Vemurafenib—Skin disorder—Etoposide—lung cancer	3.36e-05	0.00085	CcSEcCtD
Vemurafenib—Dry skin—Doxorubicin—lung cancer	3.34e-05	0.000847	CcSEcCtD
Vemurafenib—Dizziness—Vinorelbine—lung cancer	3.33e-05	0.000844	CcSEcCtD
Vemurafenib—Nervous system disorder—Paclitaxel—lung cancer	3.32e-05	0.000842	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Methotrexate—lung cancer	3.32e-05	0.000842	CcSEcCtD
Vemurafenib—Skin disorder—Paclitaxel—lung cancer	3.29e-05	0.000834	CcSEcCtD
Vemurafenib—Body temperature increased—Irinotecan—lung cancer	3.28e-05	0.000832	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Doxorubicin—lung cancer	3.28e-05	0.000832	CcSEcCtD
Vemurafenib—Decreased appetite—Cisplatin—lung cancer	3.28e-05	0.000831	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Cisplatin—lung cancer	3.26e-05	0.000825	CcSEcCtD
Vemurafenib—Infestation NOS—Methotrexate—lung cancer	3.25e-05	0.000822	CcSEcCtD
Vemurafenib—Infestation—Methotrexate—lung cancer	3.25e-05	0.000822	CcSEcCtD
Vemurafenib—Hypotension—Etoposide—lung cancer	3.23e-05	0.000818	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Methotrexate—lung cancer	3.22e-05	0.000815	CcSEcCtD
Vemurafenib—Vomiting—Vinorelbine—lung cancer	3.2e-05	0.000811	CcSEcCtD
Vemurafenib—Body temperature increased—Gemcitabine—lung cancer	3.2e-05	0.00081	CcSEcCtD
Vemurafenib—Rash—Vinorelbine—lung cancer	3.18e-05	0.000805	CcSEcCtD
Vemurafenib—Dermatitis—Vinorelbine—lung cancer	3.17e-05	0.000804	CcSEcCtD
Vemurafenib—Hypotension—Paclitaxel—lung cancer	3.17e-05	0.000802	CcSEcCtD
Vemurafenib—Headache—Vinorelbine—lung cancer	3.16e-05	0.000799	CcSEcCtD
Vemurafenib—Eosinophilia—Doxorubicin—lung cancer	3.12e-05	0.000791	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Paclitaxel—lung cancer	3.09e-05	0.000782	CcSEcCtD
Vemurafenib—Cough—Docetaxel—lung cancer	3.07e-05	0.000778	CcSEcCtD
Vemurafenib—Hypersensitivity—Irinotecan—lung cancer	3.06e-05	0.000775	CcSEcCtD
Vemurafenib—Decreased appetite—Etoposide—lung cancer	3e-05	0.000761	CcSEcCtD
Vemurafenib—Arthralgia—Docetaxel—lung cancer	3e-05	0.000759	CcSEcCtD
Vemurafenib—Myalgia—Docetaxel—lung cancer	3e-05	0.000759	CcSEcCtD
Vemurafenib—Nausea—Vinorelbine—lung cancer	2.99e-05	0.000758	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Etoposide—lung cancer	2.98e-05	0.000756	CcSEcCtD
Vemurafenib—Body temperature increased—Cisplatin—lung cancer	2.98e-05	0.000755	CcSEcCtD
Vemurafenib—Asthenia—Irinotecan—lung cancer	2.98e-05	0.000755	CcSEcCtD
Vemurafenib—Fatigue—Etoposide—lung cancer	2.98e-05	0.000755	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	2.98e-05	0.000754	CcSEcCtD
Vemurafenib—Constipation—Etoposide—lung cancer	2.96e-05	0.000749	CcSEcCtD
Vemurafenib—Decreased appetite—Paclitaxel—lung cancer	2.95e-05	0.000746	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Paclitaxel—lung cancer	2.93e-05	0.000741	CcSEcCtD
Vemurafenib—Fatigue—Paclitaxel—lung cancer	2.92e-05	0.00074	CcSEcCtD
Vemurafenib—Asthenia—Gemcitabine—lung cancer	2.9e-05	0.000736	CcSEcCtD
Vemurafenib—Constipation—Paclitaxel—lung cancer	2.9e-05	0.000734	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Doxorubicin—lung cancer	2.88e-05	0.000729	CcSEcCtD
Vemurafenib—Anaphylactic shock—Docetaxel—lung cancer	2.87e-05	0.000728	CcSEcCtD
Vemurafenib—Pruritus—Gemcitabine—lung cancer	2.86e-05	0.000725	CcSEcCtD
Vemurafenib—Infection—Docetaxel—lung cancer	2.85e-05	0.000723	CcSEcCtD
Vemurafenib—Weight decreased—Doxorubicin—lung cancer	2.85e-05	0.000722	CcSEcCtD
Vemurafenib—Diarrhoea—Irinotecan—lung cancer	2.84e-05	0.00072	CcSEcCtD
Vemurafenib—Nervous system disorder—Docetaxel—lung cancer	2.82e-05	0.000713	CcSEcCtD
Vemurafenib—Infestation NOS—Doxorubicin—lung cancer	2.81e-05	0.000712	CcSEcCtD
Vemurafenib—Infestation—Doxorubicin—lung cancer	2.81e-05	0.000712	CcSEcCtD
Vemurafenib—Skin disorder—Docetaxel—lung cancer	2.79e-05	0.000707	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Doxorubicin—lung cancer	2.79e-05	0.000706	CcSEcCtD
Vemurafenib—Hypersensitivity—Cisplatin—lung cancer	2.78e-05	0.000704	CcSEcCtD
Vemurafenib—Diarrhoea—Gemcitabine—lung cancer	2.77e-05	0.000701	CcSEcCtD
Vemurafenib—Erythema multiforme—Methotrexate—lung cancer	2.76e-05	0.000698	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Doxorubicin—lung cancer	2.76e-05	0.000698	CcSEcCtD
Vemurafenib—Dizziness—Irinotecan—lung cancer	2.75e-05	0.000696	CcSEcCtD
Vemurafenib—Body temperature increased—Etoposide—lung cancer	2.73e-05	0.000692	CcSEcCtD
Vemurafenib—Eye disorder—Methotrexate—lung cancer	2.72e-05	0.00069	CcSEcCtD
Vemurafenib—Asthenia—Cisplatin—lung cancer	2.71e-05	0.000686	CcSEcCtD
Vemurafenib—Cardiac disorder—Methotrexate—lung cancer	2.7e-05	0.000685	CcSEcCtD
Vemurafenib—Hypotension—Docetaxel—lung cancer	2.68e-05	0.00068	CcSEcCtD
Vemurafenib—Body temperature increased—Paclitaxel—lung cancer	2.68e-05	0.000679	CcSEcCtD
Vemurafenib—Angiopathy—Methotrexate—lung cancer	2.64e-05	0.00067	CcSEcCtD
Vemurafenib—Vomiting—Irinotecan—lung cancer	2.64e-05	0.000669	CcSEcCtD
Vemurafenib—Mediastinal disorder—Methotrexate—lung cancer	2.63e-05	0.000665	CcSEcCtD
Vemurafenib—Rash—Irinotecan—lung cancer	2.62e-05	0.000664	CcSEcCtD
Vemurafenib—Dermatitis—Irinotecan—lung cancer	2.62e-05	0.000663	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Docetaxel—lung cancer	2.62e-05	0.000663	CcSEcCtD
Vemurafenib—Chills—Methotrexate—lung cancer	2.61e-05	0.000662	CcSEcCtD
Vemurafenib—Headache—Irinotecan—lung cancer	2.6e-05	0.000659	CcSEcCtD
Vemurafenib—Diarrhoea—Cisplatin—lung cancer	2.58e-05	0.000654	CcSEcCtD
Vemurafenib—Alopecia—Methotrexate—lung cancer	2.57e-05	0.000652	CcSEcCtD
Vemurafenib—Vomiting—Gemcitabine—lung cancer	2.57e-05	0.000652	CcSEcCtD
Vemurafenib—Rash—Gemcitabine—lung cancer	2.55e-05	0.000646	CcSEcCtD
Vemurafenib—Dermatitis—Gemcitabine—lung cancer	2.55e-05	0.000646	CcSEcCtD
Vemurafenib—Hypersensitivity—Etoposide—lung cancer	2.55e-05	0.000645	CcSEcCtD
Vemurafenib—Malnutrition—Methotrexate—lung cancer	2.54e-05	0.000643	CcSEcCtD
Vemurafenib—Erythema—Methotrexate—lung cancer	2.54e-05	0.000643	CcSEcCtD
Vemurafenib—Headache—Gemcitabine—lung cancer	2.54e-05	0.000642	CcSEcCtD
Vemurafenib—Decreased appetite—Docetaxel—lung cancer	2.5e-05	0.000632	CcSEcCtD
Vemurafenib—Hypersensitivity—Paclitaxel—lung cancer	2.5e-05	0.000632	CcSEcCtD
Vemurafenib—Oedema peripheral—Doxorubicin—lung cancer	2.49e-05	0.00063	CcSEcCtD
Vemurafenib—Dysgeusia—Methotrexate—lung cancer	2.48e-05	0.000629	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Docetaxel—lung cancer	2.48e-05	0.000628	CcSEcCtD
Vemurafenib—Asthenia—Etoposide—lung cancer	2.48e-05	0.000628	CcSEcCtD
Vemurafenib—Connective tissue disorder—Doxorubicin—lung cancer	2.48e-05	0.000628	CcSEcCtD
Vemurafenib—Fatigue—Docetaxel—lung cancer	2.48e-05	0.000627	CcSEcCtD
Vemurafenib—Nausea—Irinotecan—lung cancer	2.47e-05	0.000625	CcSEcCtD
Vemurafenib—Constipation—Docetaxel—lung cancer	2.46e-05	0.000622	CcSEcCtD
Vemurafenib—Back pain—Methotrexate—lung cancer	2.45e-05	0.000621	CcSEcCtD
Vemurafenib—Pruritus—Etoposide—lung cancer	2.45e-05	0.000619	CcSEcCtD
Vemurafenib—Asthenia—Paclitaxel—lung cancer	2.43e-05	0.000616	CcSEcCtD
Vemurafenib—Nausea—Gemcitabine—lung cancer	2.4e-05	0.000609	CcSEcCtD
Vemurafenib—Vomiting—Cisplatin—lung cancer	2.4e-05	0.000608	CcSEcCtD
Vemurafenib—Pruritus—Paclitaxel—lung cancer	2.4e-05	0.000607	CcSEcCtD
Vemurafenib—Erythema multiforme—Doxorubicin—lung cancer	2.39e-05	0.000604	CcSEcCtD
Vemurafenib—Rash—Cisplatin—lung cancer	2.38e-05	0.000603	CcSEcCtD
Vemurafenib—Dermatitis—Cisplatin—lung cancer	2.38e-05	0.000602	CcSEcCtD
Vemurafenib—Diarrhoea—Etoposide—lung cancer	2.36e-05	0.000599	CcSEcCtD
Vemurafenib—Eye disorder—Doxorubicin—lung cancer	2.36e-05	0.000597	CcSEcCtD
Vemurafenib—Cardiac disorder—Doxorubicin—lung cancer	2.34e-05	0.000593	CcSEcCtD
Vemurafenib—Diarrhoea—Paclitaxel—lung cancer	2.32e-05	0.000587	CcSEcCtD
Vemurafenib—Angiopathy—Doxorubicin—lung cancer	2.29e-05	0.00058	CcSEcCtD
Vemurafenib—Dizziness—Etoposide—lung cancer	2.29e-05	0.000579	CcSEcCtD
Vemurafenib—Mediastinal disorder—Doxorubicin—lung cancer	2.27e-05	0.000576	CcSEcCtD
Vemurafenib—Body temperature increased—Docetaxel—lung cancer	2.27e-05	0.000575	CcSEcCtD
Vemurafenib—Chills—Doxorubicin—lung cancer	2.26e-05	0.000573	CcSEcCtD
Vemurafenib—Dizziness—Paclitaxel—lung cancer	2.24e-05	0.000568	CcSEcCtD
Vemurafenib—Nausea—Cisplatin—lung cancer	2.24e-05	0.000568	CcSEcCtD
Vemurafenib—Alopecia—Doxorubicin—lung cancer	2.23e-05	0.000565	CcSEcCtD
Vemurafenib—Cough—Methotrexate—lung cancer	2.21e-05	0.000561	CcSEcCtD
Vemurafenib—Vomiting—Etoposide—lung cancer	2.2e-05	0.000557	CcSEcCtD
Vemurafenib—Erythema—Doxorubicin—lung cancer	2.2e-05	0.000556	CcSEcCtD
Vemurafenib—Malnutrition—Doxorubicin—lung cancer	2.2e-05	0.000556	CcSEcCtD
Vemurafenib—Rash—Etoposide—lung cancer	2.18e-05	0.000552	CcSEcCtD
Vemurafenib—Dermatitis—Etoposide—lung cancer	2.18e-05	0.000551	CcSEcCtD
Vemurafenib—Headache—Etoposide—lung cancer	2.17e-05	0.000548	CcSEcCtD
Vemurafenib—Arthralgia—Methotrexate—lung cancer	2.16e-05	0.000547	CcSEcCtD
Vemurafenib—Myalgia—Methotrexate—lung cancer	2.16e-05	0.000547	CcSEcCtD
Vemurafenib—Vomiting—Paclitaxel—lung cancer	2.15e-05	0.000546	CcSEcCtD
Vemurafenib—Dysgeusia—Doxorubicin—lung cancer	2.15e-05	0.000545	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	2.14e-05	0.000543	CcSEcCtD
Vemurafenib—Rash—Paclitaxel—lung cancer	2.14e-05	0.000541	CcSEcCtD
Vemurafenib—Dermatitis—Paclitaxel—lung cancer	2.13e-05	0.000541	CcSEcCtD
Vemurafenib—Back pain—Doxorubicin—lung cancer	2.12e-05	0.000538	CcSEcCtD
Vemurafenib—Headache—Paclitaxel—lung cancer	2.12e-05	0.000538	CcSEcCtD
Vemurafenib—Hypersensitivity—Docetaxel—lung cancer	2.12e-05	0.000536	CcSEcCtD
Vemurafenib—Anaphylactic shock—Methotrexate—lung cancer	2.07e-05	0.000524	CcSEcCtD
Vemurafenib—Asthenia—Docetaxel—lung cancer	2.06e-05	0.000522	CcSEcCtD
Vemurafenib—Infection—Methotrexate—lung cancer	2.06e-05	0.000521	CcSEcCtD
Vemurafenib—Nausea—Etoposide—lung cancer	2.05e-05	0.00052	CcSEcCtD
Vemurafenib—Pruritus—Docetaxel—lung cancer	2.03e-05	0.000515	CcSEcCtD
Vemurafenib—Nervous system disorder—Methotrexate—lung cancer	2.03e-05	0.000514	CcSEcCtD
Vemurafenib—Nausea—Paclitaxel—lung cancer	2.01e-05	0.00051	CcSEcCtD
Vemurafenib—Skin disorder—Methotrexate—lung cancer	2.01e-05	0.000509	CcSEcCtD
Vemurafenib—Diarrhoea—Docetaxel—lung cancer	1.97e-05	0.000498	CcSEcCtD
Vemurafenib—Hypotension—Methotrexate—lung cancer	1.93e-05	0.00049	CcSEcCtD
Vemurafenib—Cough—Doxorubicin—lung cancer	1.92e-05	0.000485	CcSEcCtD
Vemurafenib—Dizziness—Docetaxel—lung cancer	1.9e-05	0.000481	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Methotrexate—lung cancer	1.89e-05	0.000478	CcSEcCtD
Vemurafenib—Arthralgia—Doxorubicin—lung cancer	1.87e-05	0.000474	CcSEcCtD
Vemurafenib—Myalgia—Doxorubicin—lung cancer	1.87e-05	0.000474	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	1.86e-05	0.00047	CcSEcCtD
Vemurafenib—Vomiting—Docetaxel—lung cancer	1.83e-05	0.000463	CcSEcCtD
Vemurafenib—Rash—Docetaxel—lung cancer	1.81e-05	0.000459	CcSEcCtD
Vemurafenib—Dermatitis—Docetaxel—lung cancer	1.81e-05	0.000458	CcSEcCtD
Vemurafenib—Decreased appetite—Methotrexate—lung cancer	1.8e-05	0.000456	CcSEcCtD
Vemurafenib—Headache—Docetaxel—lung cancer	1.8e-05	0.000456	CcSEcCtD
Vemurafenib—Anaphylactic shock—Doxorubicin—lung cancer	1.79e-05	0.000454	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Methotrexate—lung cancer	1.79e-05	0.000453	CcSEcCtD
Vemurafenib—Fatigue—Methotrexate—lung cancer	1.78e-05	0.000452	CcSEcCtD
Vemurafenib—Infection—Doxorubicin—lung cancer	1.78e-05	0.000451	CcSEcCtD
Vemurafenib—Nervous system disorder—Doxorubicin—lung cancer	1.76e-05	0.000445	CcSEcCtD
Vemurafenib—Skin disorder—Doxorubicin—lung cancer	1.74e-05	0.000441	CcSEcCtD
Vemurafenib—Nausea—Docetaxel—lung cancer	1.71e-05	0.000432	CcSEcCtD
Vemurafenib—Hypotension—Doxorubicin—lung cancer	1.67e-05	0.000424	CcSEcCtD
Vemurafenib—Body temperature increased—Methotrexate—lung cancer	1.64e-05	0.000415	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Doxorubicin—lung cancer	1.63e-05	0.000414	CcSEcCtD
Vemurafenib—Decreased appetite—Doxorubicin—lung cancer	1.56e-05	0.000395	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Doxorubicin—lung cancer	1.55e-05	0.000392	CcSEcCtD
Vemurafenib—Fatigue—Doxorubicin—lung cancer	1.55e-05	0.000391	CcSEcCtD
Vemurafenib—Constipation—Doxorubicin—lung cancer	1.53e-05	0.000388	CcSEcCtD
Vemurafenib—Hypersensitivity—Methotrexate—lung cancer	1.53e-05	0.000386	CcSEcCtD
Vemurafenib—Asthenia—Methotrexate—lung cancer	1.49e-05	0.000376	CcSEcCtD
Vemurafenib—Pruritus—Methotrexate—lung cancer	1.46e-05	0.000371	CcSEcCtD
Vemurafenib—Body temperature increased—Doxorubicin—lung cancer	1.42e-05	0.000359	CcSEcCtD
Vemurafenib—Diarrhoea—Methotrexate—lung cancer	1.42e-05	0.000359	CcSEcCtD
Vemurafenib—Dizziness—Methotrexate—lung cancer	1.37e-05	0.000347	CcSEcCtD
Vemurafenib—Hypersensitivity—Doxorubicin—lung cancer	1.32e-05	0.000335	CcSEcCtD
Vemurafenib—Vomiting—Methotrexate—lung cancer	1.32e-05	0.000333	CcSEcCtD
Vemurafenib—Rash—Methotrexate—lung cancer	1.31e-05	0.000331	CcSEcCtD
Vemurafenib—Dermatitis—Methotrexate—lung cancer	1.3e-05	0.00033	CcSEcCtD
Vemurafenib—Headache—Methotrexate—lung cancer	1.3e-05	0.000329	CcSEcCtD
Vemurafenib—Asthenia—Doxorubicin—lung cancer	1.29e-05	0.000326	CcSEcCtD
Vemurafenib—Pruritus—Doxorubicin—lung cancer	1.27e-05	0.000321	CcSEcCtD
Vemurafenib—Nausea—Methotrexate—lung cancer	1.23e-05	0.000311	CcSEcCtD
Vemurafenib—Diarrhoea—Doxorubicin—lung cancer	1.23e-05	0.000311	CcSEcCtD
Vemurafenib—Dizziness—Doxorubicin—lung cancer	1.19e-05	0.0003	CcSEcCtD
Vemurafenib—Vomiting—Doxorubicin—lung cancer	1.14e-05	0.000289	CcSEcCtD
Vemurafenib—Rash—Doxorubicin—lung cancer	1.13e-05	0.000286	CcSEcCtD
Vemurafenib—Dermatitis—Doxorubicin—lung cancer	1.13e-05	0.000286	CcSEcCtD
Vemurafenib—Headache—Doxorubicin—lung cancer	1.12e-05	0.000284	CcSEcCtD
Vemurafenib—Nausea—Doxorubicin—lung cancer	1.06e-05	0.00027	CcSEcCtD
Vemurafenib—RAF1—Signaling Pathways—KIT—lung cancer	1.21e-06	2.74e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—NRAS—lung cancer	1.21e-06	2.74e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTA2—lung cancer	1.2e-06	2.72e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—POMC—lung cancer	1.2e-06	2.72e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCND1—lung cancer	1.2e-06	2.72e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—JUN—lung cancer	1.2e-06	2.71e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EGF—lung cancer	1.2e-06	2.71e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ENO2—lung cancer	1.19e-06	2.69e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—HPGDS—lung cancer	1.19e-06	2.69e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—EP300—lung cancer	1.18e-06	2.68e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PPP2R1B—lung cancer	1.18e-06	2.67e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—SRC—lung cancer	1.18e-06	2.67e-05	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—AKT1—lung cancer	1.18e-06	2.67e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CREBBP—lung cancer	1.17e-06	2.65e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PIK3CA—lung cancer	1.17e-06	2.64e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MMP9—lung cancer	1.16e-06	2.64e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—lung cancer	1.16e-06	2.64e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CDKN1A—lung cancer	1.16e-06	2.63e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTA1—lung cancer	1.16e-06	2.63e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—MAPK3—lung cancer	1.16e-06	2.63e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PTEN—lung cancer	1.16e-06	2.62e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PTEN—lung cancer	1.16e-06	2.62e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSTT1—lung cancer	1.15e-06	2.61e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—POMC—lung cancer	1.15e-06	2.61e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—SRC—lung cancer	1.15e-06	2.6e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—VEGFA—lung cancer	1.15e-06	2.6e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CDKN1A—lung cancer	1.15e-06	2.6e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ABCC3—lung cancer	1.15e-06	2.6e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PTEN—lung cancer	1.14e-06	2.59e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP2E1—lung cancer	1.14e-06	2.59e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GSTP1—lung cancer	1.14e-06	2.59e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP2A6—lung cancer	1.14e-06	2.58e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GCLC—lung cancer	1.14e-06	2.58e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—BRAF—lung cancer	1.14e-06	2.58e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CDKN1A—lung cancer	1.14e-06	2.58e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—NRAS—lung cancer	1.13e-06	2.57e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	1.13e-06	2.57e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PTEN—lung cancer	1.13e-06	2.57e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NQO1—lung cancer	1.13e-06	2.56e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL6R—lung cancer	1.12e-06	2.55e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CREBBP—lung cancer	1.12e-06	2.54e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CAT—lung cancer	1.11e-06	2.52e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—AKR1C1—lung cancer	1.11e-06	2.52e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3CD—lung cancer	1.11e-06	2.51e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—STAT3—lung cancer	1.11e-06	2.51e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—NRAS—lung cancer	1.11e-06	2.51e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—EP300—lung cancer	1.1e-06	2.5e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—EP300—lung cancer	1.1e-06	2.5e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—EGFR—lung cancer	1.1e-06	2.5e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PIK3CB—lung cancer	1.1e-06	2.49e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—ALB—lung cancer	1.1e-06	2.48e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—EP300—lung cancer	1.09e-06	2.47e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTGS2—lung cancer	1.09e-06	2.47e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—MAPK3—lung cancer	1.09e-06	2.46e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—EP300—lung cancer	1.08e-06	2.45e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ABCB1—lung cancer	1.08e-06	2.45e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—HRAS—lung cancer	1.08e-06	2.45e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ENO1—lung cancer	1.08e-06	2.45e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—UGT1A1—lung cancer	1.08e-06	2.44e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	1.08e-06	2.44e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SRC—lung cancer	1.07e-06	2.43e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MAP2K1—lung cancer	1.07e-06	2.43e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3CD—lung cancer	1.06e-06	2.41e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—lung cancer	1.06e-06	2.41e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—TYMS—lung cancer	1.06e-06	2.41e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—SRC—lung cancer	1.06e-06	2.4e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—MAPK3—lung cancer	1.06e-06	2.4e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—SRC—lung cancer	1.05e-06	2.38e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GSTM1—lung cancer	1.05e-06	2.38e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—VEGFA—lung cancer	1.05e-06	2.37e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—KRAS—lung cancer	1.04e-06	2.36e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GNG11—lung cancer	1.04e-06	2.36e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—STAT3—lung cancer	1.04e-06	2.35e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NRAS—lung cancer	1.03e-06	2.34e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—IL6—lung cancer	1.03e-06	2.34e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—STAT3—lung cancer	1.02e-06	2.32e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—NRAS—lung cancer	1.02e-06	2.31e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—STK11—lung cancer	1.02e-06	2.31e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—STAT3—lung cancer	1.01e-06	2.3e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—NRAS—lung cancer	1.01e-06	2.29e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—EGFR—lung cancer	1.01e-06	2.28e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CYP1A1—lung cancer	9.94e-07	2.25e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ALDOA—lung cancer	9.9e-07	2.24e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MAPK3—lung cancer	9.9e-07	2.24e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ERCC2—lung cancer	9.86e-07	2.24e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MAPK3—lung cancer	9.78e-07	2.22e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—KRAS—lung cancer	9.77e-07	2.21e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MAPK3—lung cancer	9.69e-07	2.2e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP2E1—lung cancer	9.68e-07	2.19e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3CB—lung cancer	9.67e-07	2.19e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MYC—lung cancer	9.62e-07	2.18e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NCOA3—lung cancer	9.61e-07	2.18e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTGS2—lung cancer	9.58e-07	2.17e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NQO1—lung cancer	9.57e-07	2.17e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—PIK3CA—lung cancer	9.57e-07	2.17e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—AKT1—lung cancer	9.53e-07	2.16e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MDM2—lung cancer	9.53e-07	2.16e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—KRAS—lung cancer	9.52e-07	2.16e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MYC—lung cancer	9.51e-07	2.16e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTEN—lung cancer	9.5e-07	2.15e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MYC—lung cancer	9.43e-07	2.14e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GSTP1—lung cancer	9.43e-07	2.14e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—EGFR—lung cancer	9.41e-07	2.13e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ERBB2—lung cancer	9.4e-07	2.13e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	9.37e-07	2.12e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ADCY1—lung cancer	9.35e-07	2.12e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ABCG2—lung cancer	9.35e-07	2.12e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—EGFR—lung cancer	9.3e-07	2.11e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	9.29e-07	2.11e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MTOR—lung cancer	9.27e-07	2.1e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3CB—lung cancer	9.27e-07	2.1e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—EGFR—lung cancer	9.22e-07	2.09e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CAT—lung cancer	9.17e-07	2.08e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ENO2—lung cancer	9.17e-07	2.08e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—HPGDS—lung cancer	9.17e-07	2.08e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PPP2R1B—lung cancer	9.11e-07	2.06e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—EP300—lung cancer	9.06e-07	2.05e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—PIK3CA—lung cancer	8.97e-07	2.03e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ABCB1—lung cancer	8.92e-07	2.02e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CXCL8—lung cancer	8.91e-07	2.02e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—KRAS—lung cancer	8.89e-07	2.02e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTT1—lung cancer	8.89e-07	2.01e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—HRAS—lung cancer	8.85e-07	2.01e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GCLC—lung cancer	8.79e-07	1.99e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP2A6—lung cancer	8.79e-07	1.99e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—KRAS—lung cancer	8.79e-07	1.99e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—TYMS—lung cancer	8.76e-07	1.99e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PIK3CA—lung cancer	8.74e-07	1.98e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—KRAS—lung cancer	8.71e-07	1.97e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TP53—lung cancer	8.68e-07	1.97e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GSTM1—lung cancer	8.66e-07	1.96e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—STK11—lung cancer	8.63e-07	1.96e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—APOA1—lung cancer	8.53e-07	1.93e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CASP3—lung cancer	8.53e-07	1.93e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL2—lung cancer	8.52e-07	1.93e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL6—lung cancer	8.47e-07	1.92e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTEN—lung cancer	8.36e-07	1.89e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ENO1—lung cancer	8.33e-07	1.89e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—HRAS—lung cancer	8.3e-07	1.88e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCND1—lung cancer	8.3e-07	1.88e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—JUN—lung cancer	8.28e-07	1.88e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP1A1—lung cancer	8.21e-07	1.86e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PIK3CA—lung cancer	8.17e-07	1.85e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	8.17e-07	1.85e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ERCC2—lung cancer	8.14e-07	1.85e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—lung cancer	8.1e-07	1.84e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HRAS—lung cancer	8.09e-07	1.83e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PIK3CA—lung cancer	8.07e-07	1.83e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MMP9—lung cancer	8.06e-07	1.83e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CDKN1A—lung cancer	8.03e-07	1.82e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PTEN—lung cancer	8.01e-07	1.82e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PIK3CA—lung cancer	8e-07	1.81e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSTP1—lung cancer	7.98e-07	1.81e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—EP300—lung cancer	7.97e-07	1.81e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TP53—lung cancer	7.9e-07	1.79e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—AKT1—lung cancer	7.82e-07	1.77e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CG—lung cancer	7.79e-07	1.77e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CAT—lung cancer	7.77e-07	1.76e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL6—lung cancer	7.74e-07	1.75e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—lung cancer	7.73e-07	1.75e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EP300—lung cancer	7.64e-07	1.73e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—HRAS—lung cancer	7.56e-07	1.71e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ABCB1—lung cancer	7.56e-07	1.71e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP2E1—lung cancer	7.47e-07	1.69e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—HRAS—lung cancer	7.47e-07	1.69e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SRC—lung cancer	7.43e-07	1.68e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—TYMS—lung cancer	7.42e-07	1.68e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—POMC—lung cancer	7.41e-07	1.68e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—HRAS—lung cancer	7.4e-07	1.68e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NQO1—lung cancer	7.39e-07	1.67e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSTM1—lung cancer	7.34e-07	1.66e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—AKT1—lung cancer	7.33e-07	1.66e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—VEGFA—lung cancer	7.24e-07	1.64e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL6—lung cancer	7.23e-07	1.64e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CREBBP—lung cancer	7.22e-07	1.64e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—STAT3—lung cancer	7.17e-07	1.62e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NRAS—lung cancer	7.15e-07	1.62e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—IL6—lung cancer	7.15e-07	1.62e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—AKT1—lung cancer	7.14e-07	1.62e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—IL6—lung cancer	7.09e-07	1.61e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—APOA1—lung cancer	7.04e-07	1.6e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP1A1—lung cancer	6.96e-07	1.58e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ERCC2—lung cancer	6.9e-07	1.56e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CD—lung cancer	6.85e-07	1.55e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MAPK3—lung cancer	6.85e-07	1.55e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PIK3CA—lung cancer	6.7e-07	1.52e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—AKT1—lung cancer	6.67e-07	1.51e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—STK11—lung cancer	6.66e-07	1.51e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MYC—lung cancer	6.66e-07	1.51e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—AKT1—lung cancer	6.59e-07	1.49e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—AKT1—lung cancer	6.54e-07	1.48e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EGFR—lung cancer	6.51e-07	1.48e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CG—lung cancer	6.43e-07	1.46e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTP1—lung cancer	6.16e-07	1.4e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—KRAS—lung cancer	6.15e-07	1.39e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—POMC—lung cancer	6.12e-07	1.39e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CAT—lung cancer	6e-07	1.36e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CB—lung cancer	5.97e-07	1.35e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—APOA1—lung cancer	5.97e-07	1.35e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CREBBP—lung cancer	5.96e-07	1.35e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTGS2—lung cancer	5.91e-07	1.34e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3CA—lung cancer	5.9e-07	1.34e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ABCB1—lung cancer	5.83e-07	1.32e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—TYMS—lung cancer	5.73e-07	1.3e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	5.71e-07	1.3e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTM1—lung cancer	5.66e-07	1.28e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CD—lung cancer	5.65e-07	1.28e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3CA—lung cancer	5.65e-07	1.28e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ALB—lung cancer	5.58e-07	1.26e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—AKT1—lung cancer	5.47e-07	1.24e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TP53—lung cancer	5.47e-07	1.24e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CG—lung cancer	5.45e-07	1.23e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP1A1—lung cancer	5.37e-07	1.22e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ERCC2—lung cancer	5.32e-07	1.21e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HRAS—lung cancer	5.23e-07	1.19e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—POMC—lung cancer	5.19e-07	1.18e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTEN—lung cancer	5.16e-07	1.17e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CREBBP—lung cancer	5.05e-07	1.14e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL6—lung cancer	5.01e-07	1.13e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CB—lung cancer	4.93e-07	1.12e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—EP300—lung cancer	4.92e-07	1.11e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTGS2—lung cancer	4.88e-07	1.11e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—AKT1—lung cancer	4.82e-07	1.09e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CD—lung cancer	4.79e-07	1.09e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ALB—lung cancer	4.73e-07	1.07e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AKT1—lung cancer	4.62e-07	1.05e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—APOA1—lung cancer	4.61e-07	1.04e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTEN—lung cancer	4.26e-07	9.65e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CG—lung cancer	4.2e-07	9.53e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CB—lung cancer	4.17e-07	9.46e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTGS2—lung cancer	4.14e-07	9.37e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—EP300—lung cancer	4.06e-07	9.2e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—POMC—lung cancer	4e-07	9.07e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CREBBP—lung cancer	3.9e-07	8.84e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CD—lung cancer	3.7e-07	8.38e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ALB—lung cancer	3.65e-07	8.27e-06	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CA—lung cancer	3.64e-07	8.25e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTEN—lung cancer	3.61e-07	8.18e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—EP300—lung cancer	3.44e-07	7.8e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CB—lung cancer	3.22e-07	7.3e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTGS2—lung cancer	3.19e-07	7.24e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CA—lung cancer	3e-07	6.81e-06	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—AKT1—lung cancer	2.97e-07	6.74e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTEN—lung cancer	2.78e-07	6.31e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—EP300—lung cancer	2.66e-07	6.02e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CA—lung cancer	2.55e-07	5.77e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—AKT1—lung cancer	2.45e-07	5.56e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—AKT1—lung cancer	2.08e-07	4.71e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CA—lung cancer	1.96e-07	4.45e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—AKT1—lung cancer	1.6e-07	3.64e-06	CbGpPWpGaD
